874 1030
Table 2 – Baseline characteristics of prospective studies
Study ID (year), country,
design, recruitment period
PROM tool used
Interventions
N
Age: mean (SD),
median [range]
{95% CI}
FU (mo):
mean (SD),
median [range]
T stage
Gleason score:
n
or mean (SD)
PSA:
n
mean (SD),
median [range]
Comorbidity
Bacon
(2001)
a [14] , USA,
prospective, 1993–1998
Radical
prostatectomy
421 68
Up to 60 mo
T1: (0%)
T2: (95%)
Unspecified: (0%)
Missing: (5%)
2–4: (7%)
5–6: (57%)
7–10: (29%)
Missing: (7%)
NR
Heart disease (12%)
High blood pressure (34%)
High cholesterol (51%)
Diabetes (5%)
Stroke (1%)
Arthritis (5%)
Missing (2%)
UCLA-PCI
EBRT
221 75
T1: (1%)
T2: (84%)
Unspecified: (5%)
Missing: (10%)
2–4: (13%)
5–6: (39%)
7–10: (28%)
Missing: (19%)
Heart disease (24%)
High blood pressure (48%)
High cholesterol (50%)
Diabetes (11%)
Stroke (4%)
Arthritis (8%)
Missing (5%)
Brachytherapy
69 71
T1: (1%)
T2: (81%)
Unspecified: (3%)
Missing: (14%)
2–4: (13%)
5 -6: (51%)
7-10: (22%)
Missing: (14%)
Heart disease (17%)
High blood pressure (52%)
High cholesterol (48%)
Diabetes (0%)
Stroke (4%)
Arthritis (4%)
Missing (9%)
Barocas
(2017)
b [30] , USA,
prospective, 2011–2012
Radical
prostatectomy
1523 61.5{61.1–61.8}
40 [38–45]
T1c: 1140 (75%)
T2: 380 (25%)
3 + 3: 744 (49%)
3 + 4: 458 (30%)
4 + 3: 170 (11%)
8–10: 147 (10%)
0–4: 334 (22%)
4.1–10: 1018 (67%)
10.1–20: 133 (9%)
>
20: 38 (2%)
Total Illness Burden Index
0–2: 481 (33%)
3–4: 624 (43%)
5: 343 (24%)
EPIC
EBRT
598 68.1{67.6–68.7}
T1c: 436 (73%)
T2: 161 (27%)
3 + 3: 210 (35%)
3 + 4: 201 (34%)
4 + 3: 86 (14%)
8-10: 99 (17%)
0-4: 85 (14%)
4.1-10: 394 (66%)
10.1-20: 86 (14%)
>
20: 33 (6%)
Total Illness Burden Index
0-2: 101 (17%)
3-4: 238 (41%)
5: 241 (42%)
Borchers
(2004)
[15]
,Germany, prospective,
1999–2004?
Radical
prostatectomy +
NS
38 59.2 (4.6)
26 [12–60]
cT1c: 22 (58%)
T2a: 16 (42%)
(2–4): 14 (38%)
(5–6): 24 (62%)
6.4 (2.8)
NR
EORTC QLQ-C30
Radical
prostatectomy,
no NS
42 65.2 (4.9)
T1c: 19 (45%)
T2a: 23 (55%)
(2–4): 18 (42%)
(5–6): 24 (58%)
6.6 (2.6)
Brachytherapy
52 66.5 (6.0)
T1c: 23 (44%)
T2a: 39 (56%)
(2–4): 21 (40%)
(5–6): 31 (60%)
6.6 (2.6)
Evans
(2015)
[16]
, USA,
prospective, patients
for brachytherapy and
IMRT were enrolled from
2003 to 2006 and SBRT
patients from 2007 to 2011
Brachytherapy
262 65 (7.4)
24
T1: 221 (84%)
T2:41 (16%)
2–6: 206 (79%)
7: 55 (21%)
8–10: 1 (0.4%)
N/A: 0
5.0 (2.8)
NR
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 6 9 – 8 8 5
874